Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H19N3O4S |
Molecular Weight | 349.405 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12[C@@H](C)C(S[C@@H]3CN4C=CN=C4C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O
InChI
InChIKey=SYFIHQJVKJGGGB-SXLYUPOASA-N
InChI=1S/C16H19N3O4S/c1-7-12-11(8(2)20)15(21)19(12)13(16(22)23)14(7)24-9-5-10-17-3-4-18(10)6-9/h3-4,7-9,11-12,20H,5-6H2,1-2H3,(H,22,23)/t7-,8-,9+,11-,12-/m1/s1
Molecular Formula | C16H19N3O4S |
Molecular Weight | 349.405 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:16:20 GMT 2023
by
admin
on
Sat Dec 16 10:16:20 GMT 2023
|
Record UNII |
VL8A7ME6X8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
VL8A7ME6X8
Created by
admin on Sat Dec 16 10:16:20 GMT 2023 , Edited by admin on Sat Dec 16 10:16:20 GMT 2023
|
PRIMARY | |||
|
DTXSID501338049
Created by
admin on Sat Dec 16 10:16:20 GMT 2023 , Edited by admin on Sat Dec 16 10:16:20 GMT 2023
|
PRIMARY | |||
|
9819755
Created by
admin on Sat Dec 16 10:16:20 GMT 2023 , Edited by admin on Sat Dec 16 10:16:20 GMT 2023
|
PRIMARY | |||
|
DU 6681
Created by
admin on Sat Dec 16 10:16:20 GMT 2023 , Edited by admin on Sat Dec 16 10:16:20 GMT 2023
|
PRIMARY | |||
|
129951-17-3
Created by
admin on Sat Dec 16 10:16:20 GMT 2023 , Edited by admin on Sat Dec 16 10:16:20 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
DZ-2640 is the ester-type oral carbapenem prodrug of an active parent compound, DU-6681. The pharmacokinetics and safety of DU-6681 were investigated in six studies after oral administration of a single dose of DZ-2640 to healthy male Japanese volunteers at doses of 25, 50, 100, 200, and 400 mg (as the equivalents of DU-6681) in the fasted state.
|